Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

UnitedHealth's dip offers long-term value, backed by strong fundamentals, rising dividends, and growth potential. Learn why ...

The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.

The health insurer has suffered mounting problems and backlash since the fatal shooting of former CEO Brian Thompson.

Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...

UNH's CEO pledges reform after rare earnings miss as rising Medicare Advantage costs squeeze margins and spook investors.

UNH shares have plunged YTD, but regulatory risks, cost pressures and earnings downgrades keep it far from a bargain.